Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: A gynecologic oncology group study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 4, 2007, Pages 428-431

  Garcia, Agustin A ^a   Blessing, John A ^b   Vaccarello, Luis ^c   Roman, Lynda D ^d   Mackey, Denise ^e  

^a Premiere Oncology   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Gynecologic Oncology   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Four Penn Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTITUTIONAL TOXICITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PAIN; SIDE EFFECT; SINUS TACHYCARDIA; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; UTERINE CERVICAL NEOPLASMS;

EID: 34548437625     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31803377c8     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Thigpen JT, Shingelton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer. 1981;48:899-903.
3. Sutton GP, Blessing JA, Adcock L, et al. Phase II study of ifosfamide and mesna in patients with previously treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs. 1989;7:341-343.
4. Muderspach LI, Blessing JA, Levenback C, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81:213-215.
5. Schilder RJ, Blessing JA, Morgan M, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000;76:204-207.
6. Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:639-643.
7. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1997;14:792-795.
8. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
9. Ringel I, Band Horwitz S. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83:288-291.
10. Riou JF, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun. 1992;187:167-170.
11. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour of 6-hour intravenous infusion. J Clin Oncol. 1993;11:950-958.
12. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993;53:1037-1042.
13. Bisset D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP56976) administered as a 24-hour infusion. Cancer Res. 1993;53:523-527.
14. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of taxotere: five-day schedule. J Natl Cancer Inst. 1992;84:1781-1788.
15. Mouridsen H, Harvey V, Semiglazov V, et al. Phase III study of docetaxel 100 versus 75 verus 60 mg/m2 as second line chemotherapy in advanced breast cancer [Abstract 327]. Breast Cancer Res Treat 2002;76(suppl 1):88.
16. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel resistant metastatic breast cancer. J Clin Oncol. 1998;16:3362-3368.
17. Fosella FV, Soo Lee J, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol. 1994;12:1238-1244.
18. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
19. Dreyfus AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672-1678.
20. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-135.
21. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542-5551.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
23. Chen TT, Ng T. Optimal flexible designs in Phase II clinical trials. Stat Med 1998;17:2301-2312.
24. Kudelka AP, Verschraegen CF, Levy T, et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1996;7:398-401.
25. Vallejo CT, Machiavelli MR, Perez JE, et al. Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical carcinoma. Am J Clin Oncol. 2003;26:477-482.
26. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1079-1085.
27. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-171.
28. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:3113-3119.
29. Long HJ, Bundy BN, Grendys EC Jr, et al. Randomized phase III study of cisplatin versus cisplatin plus topotecan versus MVAC in stage IVB recurrent or persistent carcinoma of the cervix. Gynecol Oncol. 2004;92:397.